Galapagos creates new subscription right plan
January 26 2022 - 4:40PM
Galapagos creates new subscription right plan
Mechelen, Belgium;
26 January 2022,
22.40 CET;
regulated information –
Galapagos NV (Euronext &
NASDAQ: GLPG) announced today that its
supervisory board created
1,000,000 subscription rights
under a new
subscription right plan for the benefit
of a member of the personnel of the
Company.
On 26 January 2022, the supervisory board of
Galapagos approved “Subscription Right Plan 2022 (B)”, intended for
a new member of the personnel of the Company, within the framework
of the authorized capital. Under this subscription right plan,
1,000,000 subscription rights were created, subject to acceptance.
Dr. Paul Stoffels will ultimately become the new Subscription
Right Holder under the scheme.
The subscription rights have an exercise term of
eight years as of the date of the offer and have an exercise price
of €50. The subscription rights can in principle not be exercised
prior to 1 January 2026. Each subscription right gives
the right to subscribe to one new Galapagos share. Should the
subscription rights be exercised, Galapagos will apply for the
listing of the resulting new shares on a regulated stock market.
The subscription rights as such will not be listed on any stock
market.
Galapagos’ total share capital currently amounts
to €354,582,005.11; the total number of securities conferring
voting rights is 65,552,721, which is also the total number of
voting rights (the “denominator”), and all securities conferring
voting rights and all voting rights are of the same category. The
total number of rights to subscribe to not yet issued securities
conferring voting rights is (i) 8,595,522 subscription rights under
several outstanding employee subscription right plans, which equals
8,595,522 voting rights that may result from the exercise of those
subscription rights, and (ii) one subscription right issued to
Gilead Therapeutics to subscribe for a maximum number of shares
that is sufficient to bring the shareholding of Gilead and its
affiliates to 29.9% of the actually issued and outstanding shares
after the exercise of the subscription right. This excludes the
1,000,000 subscription rights of Subscription Right Plan 2022 (B),
which were created subject to acceptance. Galapagos does not have
any convertible bonds or shares without voting rights
outstanding.
About
GalapagosGalapagos NV discovers, develops, and
commercializes small molecule medicines with novel modes of action.
Our pipeline comprises discovery through Phase 3 programs in
inflammation, fibrosis, and other indications. Our ambition is to
become a leading global biopharmaceutical company focused on the
discovery, development, and commercialization of innovative
medicines. More information at www.glpg.com.
ContactInvestors:Sofie
Van GijselHead of Investor Relations+1 781 296 1143
Sandra CauwenberghsDirector Investor Relations+32 495 58 46
63ir@glpg.com
Media:Marieke VermeerschHead of Corporate
Communication+32 479 490 603communications@glpg.com
Forward-looking statements
This release may contain forward-looking
statements. Such forward-looking statements are not guarantees of
future results. These forward-looking statements speak only as of
the date of publication of this document. Galapagos expressly
disclaims any obligation to update any forward-looking statements
in this document, unless specifically required by law or
regulation.
- Galapagos creates new subscription right plan
Galapagos (EU:GLPG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Galapagos (EU:GLPG)
Historical Stock Chart
From Jul 2023 to Jul 2024